Abstract
Purpose: To assess whether phenytoin affects the pharmacokinetics of the dihydropyridine calcium antagonist nisoldipine. Methods: Twelve patients with epilepsy receiving chronic phenytoin therapy and 12 healthy control subjects matched for age and gender received a single oral dose of nisoldipine (40 and 20 mg, respectively). Blood samples were collected for up to 48 h for estimation of plasma nisoldipine levels by capillary gas chromatography. Results: Mean plasma nisoldipine concentrations were much lower in the patients. Geometric means for areas under the concentration-time curve (AUC(0-tn) normalized to a 20-mg dose were 1.6 μg/L/h (95% confidence intervals, 0.6-3.8 μg/L/h) in the patients compared with 15.2 (10.7-21.6) μg/L/h in control subjects (p
| Original language | English |
|---|---|
| Pages (from-to) | 1107-1110 |
| Number of pages | 4 |
| Journal | Epilepsia |
| Volume | 37 |
| Issue number | 11 |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- Drug interaction
- Epilepsy
- Nisoldipine
- Pharmacokinetics
- Phenytoin
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
Reduced plasma nisoldipine concentrations phenytoin-treated patients with epilepsy. / Michelucci, R.; Cipolla, G.; Passarelli, D.; Gatti, G.; Ochan, M.; Heinig, R.; Tassinari, C. A.; Perucca, E.
In: Epilepsia, Vol. 37, No. 11, 1996, p. 1107-1110.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reduced plasma nisoldipine concentrations phenytoin-treated patients with epilepsy
AU - Michelucci, R.
AU - Cipolla, G.
AU - Passarelli, D.
AU - Gatti, G.
AU - Ochan, M.
AU - Heinig, R.
AU - Tassinari, C. A.
AU - Perucca, E.
PY - 1996
Y1 - 1996
N2 - Purpose: To assess whether phenytoin affects the pharmacokinetics of the dihydropyridine calcium antagonist nisoldipine. Methods: Twelve patients with epilepsy receiving chronic phenytoin therapy and 12 healthy control subjects matched for age and gender received a single oral dose of nisoldipine (40 and 20 mg, respectively). Blood samples were collected for up to 48 h for estimation of plasma nisoldipine levels by capillary gas chromatography. Results: Mean plasma nisoldipine concentrations were much lower in the patients. Geometric means for areas under the concentration-time curve (AUC(0-tn) normalized to a 20-mg dose were 1.6 μg/L/h (95% confidence intervals, 0.6-3.8 μg/L/h) in the patients compared with 15.2 (10.7-21.6) μg/L/h in control subjects (p
AB - Purpose: To assess whether phenytoin affects the pharmacokinetics of the dihydropyridine calcium antagonist nisoldipine. Methods: Twelve patients with epilepsy receiving chronic phenytoin therapy and 12 healthy control subjects matched for age and gender received a single oral dose of nisoldipine (40 and 20 mg, respectively). Blood samples were collected for up to 48 h for estimation of plasma nisoldipine levels by capillary gas chromatography. Results: Mean plasma nisoldipine concentrations were much lower in the patients. Geometric means for areas under the concentration-time curve (AUC(0-tn) normalized to a 20-mg dose were 1.6 μg/L/h (95% confidence intervals, 0.6-3.8 μg/L/h) in the patients compared with 15.2 (10.7-21.6) μg/L/h in control subjects (p
KW - Drug interaction
KW - Epilepsy
KW - Nisoldipine
KW - Pharmacokinetics
KW - Phenytoin
UR - http://www.scopus.com/inward/record.url?scp=0029798966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029798966&partnerID=8YFLogxK
M3 - Article
C2 - 8917062
AN - SCOPUS:0029798966
VL - 37
SP - 1107
EP - 1110
JO - Epilepsia
JF - Epilepsia
SN - 0013-9580
IS - 11
ER -